Lung Cancer
Volume 55, Issue 1 , Pages 75-78 , January 2007

FDG-PET maximum standardised uptake value is associated with variation in survival: Analysis of 498 lung cancer patients

  • Andrew Davies

      Affiliations

    • The Thoracic Unit, Guy's Hospital, London SE1 9RT, United Kingdom
    • ,
  • Carol Tan

      Affiliations

    • The Thoracic Unit, Guy's Hospital, London SE1 9RT, United Kingdom
    • ,
  • Christos Paschalides

      Affiliations

    • Clinical Operational Research Unit, UCL, London, United Kingdom
    • ,
  • Sally F. Barrington

      Affiliations

    • PET Imaging Centre, St. Thomas’ Hospital, London, United Kingdom
    • ,
  • Mike O’Doherty

      Affiliations

    • PET Imaging Centre, St. Thomas’ Hospital, London, United Kingdom
    • ,
  • Martin Utley

      Affiliations

    • Clinical Operational Research Unit, UCL, London, United Kingdom
    • ,
  • Tom Treasure

      Affiliations

    • The Thoracic Unit, Guy's Hospital, London SE1 9RT, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 79 57 16 87 54; fax: +44 20 77 01 87 37.

Received 4 July 2006 ,Revised 13 September 2006 ,Accepted 18 September 2006.

References 

  1. Ahuja V, Coleman RE, Herndon J, Patz EF. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer. 1998;83:918–924
  2. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximum standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255–3260
  3. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005;130:151–159
  4. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201–3206
  5. Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Ogushi M, et al. 18F- FDG Uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002;43:39–45
  6. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. [18F] Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23:1136–1143
  7. Jeong HJ, Min JJ, Park JM, Chung JK, Kim BT, Jeong JM, et al. Determination of the prognostic value of [18F]Fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun. 2002;23:865–870
  8. Borst GR, Belderbos JS, Boellaard R, Comans EF, De Jaeger K, Lammertsma AA, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005;41:1533–1541
  9. Brenner H, Rachet B. Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. Eur J Cancer. 2004;40:2494–2501
  10. Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride- 18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg. 1995;60:1348–1352
  11. Atkins CD. Overestimation of the prognostic significance of SUV measurement by positron emission tomography for non-small-cell lung cancer. J Clin Oncol. 2005;23:6799–6800

PII: S0169-5002(06)00489-2

doi: 10.1016/j.lungcan.2006.09.010

Lung Cancer
Volume 55, Issue 1 , Pages 75-78 , January 2007

Article Tools

* Image Usage & Resolution